Search

German billionaire Christian Angermayer, along with investors Peter Thiel and Balaji Srinivasan, is investing $2.5 million into the Enhanced Games, a modern-day Olympics that allows athletes to use performance-enhancing drugs under medical supervision. The project aims to offer a $1 million prize for breaking world records in sprinting and swimming. Angermayer believes that this international sporting event focused on pushing the limits of human potential will surpass the traditional Olympics. He is known for his diverse investment portfolio, which includes cryptocurrency, psychedelic drugs, and brain implants. [Extracted from the article]

Arrowhead Pharmaceuticals presented preclinical data and detailed its plans to advance two next generation RNAi-based candidates, ARO-INHBE and ARO-ALK7, into upcoming clinical studies for the treatment of obesity and metabolic [...]

The article discusses clinical trials focused on evaluating the effectiveness of antisense oligonucleotides (ASO) therapy for rare genetic neurological diseases. Topics explored include the chemical modification of DNA or RNA depending on the treatment needs of a particular ailment, the approval of the antisense drug Spinraza for the treatment of spinal muscular atrophy (SMA), and the need for further studies into ASO technology and RNA interference.

A patent application titled "Lithium Reagents And Their Uses In Solid Phase Synthesis" was published online by inventors from San Diego, CA. The application focuses on the use of lithium to efficiently cleave solid support-bound compounds, resulting in alcohol-containing compounds. The method aims to reduce reaction time, quenching steps, and nucleophile-driven by-products, extending to all oligonucleotides with 3'- and/or 5'-modifications. The application also discusses methods for removing UnySupport solid support during the synthesis of 3'-Tri-GalNAc conjugated oligonucleotides. [Extracted from the article]

A recent study conducted by University College London (UCL) focused on the use of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The research found that vutrisiran, an RNA interference therapeutic agent, led to a lower risk of death from any cause and cardiovascular events compared to a placebo. Additionally, vutrisiran preserved functional capacity and quality of life in patients with ATTR-CM. This study was supported by Alnylam Pharmaceuticals and has been peer-reviewed. [Extracted from the article]

Researchers from Ben-Gurion University of the Negev conducted a study on the effects of the degree of substitution (DS) and molecular weight (Mw) of quaternized starch (Q-Starch) on the transfection efficacy of a starch-based siRNA delivery system for gene therapy in cancers. The study found that reducing the DS of Q-Starch decreased electrostatic interactions with siRNA, leading to improved gene silencing capabilities and enhanced transfection efficacy. The research highlights the importance of polysaccharide Mw in determining the effectiveness of siRNA delivery systems, providing valuable insights for future developments in cancer gene therapy. [Extracted from the article]

The article discusses new research from the Florida Institute of Technology on amyloid proteins and their role in Alzheimer's disease. The study shows that activating the heat shock response pathway can protect against tau toxicity, a key factor in the disease. Small-molecule activators of this pathway have shown beneficial effects, expanding the potential for therapeutic strategies in Alzheimer's disease. The research highlights the importance of understanding proteotoxicity in neurodegenerative diseases. [Extracted from the article]

A recent study from the Chinese Academy of Sciences explores the role of pyroptosis in the oyster Crassostrea hongkongensis' immune response to bacterial infections. The research focuses on the activity of Ch GSDME, a gasdermin protein cleaved by inflammatory caspase-1, and its impact on cell death during Vibrio coralliilyticus infection. The study demonstrates that pyroptosis-related genes Ch CASP1 and Ch GSDME play crucial roles in mediating cell death in response to bacterial challenges in oysters. [Extracted from the article]

This article discusses the solute carrier (SLC) superfamily, a group of proteins that facilitate the transport of various substances across cell membranes. There are approximately 450 different SLCs found in different parts of cells. Dysfunction of SLC transporters is associated with many human diseases, making them an important target for drug development. The article presents a study that mapped the protein-protein interactions of 396 SLCs, providing valuable information for researchers in this field. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A study conducted at the University of the Witwatersrand in Gauteng, South Africa, explores the potential of host-directed therapies (HDTs) in antiviral therapy. HDTs involve modifying host factors and immune responses to restrict viral replication and improve patient outcomes. The study highlights the use of gene-editing tools like CRISPR-Cas9 to manipulate host genes linked to viral processes, as well as the exploration of probiotics to enhance immune responses. While these advancements offer promising avenues for improved patient outcomes, further research and clinical evaluation are needed to ensure safety and efficacy. [Extracted from the article]

A patent application has been filed by inventors from the University of Texas System for a gene therapy treatment for Angelman Syndrome, a genetic disorder that affects the nervous system. The therapy involves using recombinant adeno-associated viral (AAV) vectors to deliver short hairpin RNA (shRNA) molecules that target the gene responsible for the syndrome. The patent application describes the specific sequences of nucleic acids used in the therapy and the methods of administration. This research provides a potential treatment option for Angelman Syndrome, which currently has no cure. [Extracted from the article]

A new report from Kyoto Pharmaceutical University discusses research findings on Dual-Specificity Phosphatases, specifically focusing on the atypical dual specificity phosphatase DUSP15 and its role in regulating Jak1-mediated Stat3 activation. The study found that DUSP15 functions as a positive feedback regulator in the Jak1/STAT3 signaling cascade. This research was funded by Grants-in-Aid for Scientific Research and other foundations. For more information, readers can refer to the article "The Atypical Dual Specificity Phosphatase Dusp15 Regulates Jak1-mediated Stat3 Activation" published in Biological and Pharmaceutical Bulletin. [Extracted from the article]

A new report discusses research on the potential benefits of Salvia leucantha, a perennial herb, in treating Alzheimer's disease (AD). The study conducted by Southwest Forestry University in China found that extracts of S. leucantha could delay paralysis and extend the lifespan of nematodes used as a model for AD. The researchers identified a gene called gst-5 that was up-regulated by the extracts, suggesting that the active components in S. leucantha may have anti-AD properties. This study provides insights into the potential therapeutic effects of S. leucantha in treating AD. [Extracted from the article]

A recent study conducted by the Chinese University of Hong Kong has investigated the use of a novel inhibitor called PBA2 in the treatment of chronic myeloid leukemia (CML). The study found that PBA2 exhibited higher anticancer effects than the current standard treatment, imatinib, in CML cells with both wild-type and T315I-mutated BCR-ABL. The researchers concluded that targeting the b-catenin/CBP pathway, regardless of BCR-ABL mutation status, could be a promising strategy for treating CML. This research provides valuable insights into potential new therapies for CML patients. [Extracted from the article]

Researchers from Arbutus Biopharma Corporation have developed a patent application for a new lipid formulation called serum-stable nucleic acid-lipid particles (SNALP) that can deliver therapeutic agents for the treatment of cancer. These lipid particles have shown increased potency and tolerability compared to other nucleic acid-lipid particle compositions. The formulations consist of nucleic acids, cationic lipids, non-cationic lipids, and conjugated lipids that prevent particle aggregation. This patent application describes the novel lipid formulation and its potential for safe and effective delivery of therapeutic agents for cancer treatment. [Extracted from the article]

A patent application titled "Compositions And Methods Of Treating Facioscapulohumeral Muscular Dystrophy" is currently being reviewed by the US Patent and Trademark Office. The application describes a method for treating Facioscapulohumeral muscular dystrophy (FSHD) using a polynucleic acid conjugate that targets a specific gene associated with FSHD. This conjugate mediates RNA interference against the gene, reducing the quantity of the mRNA transcript and alleviating muscle atrophy and other symptoms of FSHD. The patent application also discusses the use of modified nucleotides and linkers in the polynucleic acid molecule conjugate, as well as the formulation of a pharmaceutical composition for various routes of administration. FSHD is a genetic disorder that affects muscle function and can also impact vision, hearing, and the heart or lungs. [Extracted from the article]

Researchers from Soochow University in Suzhou, China have developed biomimetic nanocomplexes (NCs) to deliver siRNA targeted at microglia to modulate the inflammatory cerebral microenvironment in post-stroke ischemia-reperfusion (IR) injury. The NCs consist of a cationic nano-core and an outer shell made from a platelet-microglia hybrid membrane. The NCs are able to accumulate at the lesion site, penetrate the blood-brain barrier, and enter microglia to release siRNA and silence sphingosine kinase 1 (SPHK-1), thereby remodeling the inflammatory microenvironment and protecting the neurovascular unit. This bio-inspired strategy shows promise for gene therapy against cerebral diseases. [Extracted from the article]

Researchers at the National Research Center have conducted a study on cytokines, specifically focusing on allergic rhinitis (AR), an inflammatory disease of the upper respiratory tract. AR affects a significant portion of the global population, with a prevalence of 18% to 30% in the Russian Federation. The researchers emphasize the economic burden and potential development of more severe pathology associated with AR. They highlight the role of proinflammatory cytokines, such as IL-25 and TSLP, in the pathogenesis of AR and propose the use of synthetic miRNA molecules to block the expression of these cytokine genes. The study provides insights into potential therapeutic approaches for AR. [Extracted from the article]

A recent preprint abstract discusses the roles of EGO-1 and RRF-1 in regulating germline exo-RNAi efficiency in Caenorhabditis elegans. The study found that EGO-1 plays a dual role in germline exo-RNAi, both mediating target silencing through its RNA-dependent RNA polymerase activity and fine-tuning germ granule function or downstream processes. The researchers observed germline exo-RNAi defects in ego-1(S1198L) mutants, which were partially restored by inhibiting hrde-1, cde-1, and znfx-1. These findings provide insights into the coordination of exo-RNAi processes in the germline of C. elegans. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted by researchers from the Royal College of Surgeons explored the role of WNT4 expression in Dupuytren's disease (DD), a fibro-proliferative disorder. The study aimed to determine if the loss of WNT4 expression triggered similar changes in the transcriptome of healthy skin fibroblasts. The researchers found that downregulation of WNT4 in normal skin fibroblasts led to changes resembling those seen in DD, suggesting that WNT4 downregulation may be a key driver of the disease. This research provides valuable insights into the molecular mechanisms underlying DD and may contribute to the development of targeted therapies. [Extracted from the article]

A new RNAi biotech is breaking ground with $135 million and John Maraganore holding the key to the city. [ABSTRACT FROM AUTHOR]

A new study from Ganpat University explores the use of fluorescent liposomes in cancer research. These small lipid vesicles can encapsulate fluorescent dyes, allowing for precise visualization and monitoring of their targeted delivery to cancer cells. The study discusses the structural features, labeling techniques, targeting strategies, and challenges and opportunities associated with fluorescent liposomes. It also highlights their role in enhancing cancer diagnosis through various imaging modalities and improving cancer treatment through drug delivery mechanisms. The research concludes that fluorescent liposomes have a multifaceted impact on advancing cancer diagnosis and treatment. [Extracted from the article]

A recent study conducted by researchers at Yangzhou University in China has revealed new findings on cancer gene therapy using Newcastle disease virus (NDV). The study focused on the role of the Endosomal Sorting Complex Required for Transport (ESCRT) machinery in regulating NDV replication in tumor cells. The researchers found that knockdown of certain ESCRT components, particularly HRS, significantly impaired NDV replication and viral budding in HeLa cells. These findings provide valuable insights for the development of NDV-based oncolytic therapies. [Extracted from the article]

A new report from the National Institute of Pharmaceutical Education and Research in Telangana, India discusses the potential of gene therapy as an effective treatment for cancer. The researchers highlight the ability of gene therapy to target oncogenes and improve the selectivity and effectiveness of anticancer therapy. However, conventional gene therapy has limitations, such as low therapeutic effectiveness and rapid degradation of genetic material. To address these issues, researchers are exploring the use of multifunctional nanoparticles to enhance therapeutic efficacy and limit degradation. The study explores various gene modulation techniques and nanoscale vectors made of polymers, lipids, and inorganic materials. These vectors are being investigated for their potential to deliver genetic material specifically to cancer cells, with the aim of advancing targeted cancer therapy. [Extracted from the article]

A recent study published in Nature Nanotechnology by researchers from the Chinese Academy of Sciences has found that cholesterol-enriched exosomes can improve the delivery of short interfering RNA (siRNA) for gene therapy. Exosomes are nanoscale extracellular vesicles that have shown promise in siRNA delivery due to their biocompatibility and tissue targeting ability. The researchers discovered that increasing the cholesterol content in exosomes enhanced their interaction with target cells, allowing for direct delivery of siRNA to the cytoplasm and overcoming the issue of lysosomal degradation. In vitro and in vivo experiments demonstrated the effectiveness of cholesterol-enriched exosomes in delivering siRNA and inhibiting tumor growth. This research offers potential for the development of safer and more efficient gene therapy strategies. [Extracted from the article]

This article discusses an iterative approach to improve the accuracy of basecalling in nanopore sequencing, specifically for therapeutic RNA quality control. The authors explain that nucleotide modifications can cause errors in basecalling, and their approach aims to address this issue. They demonstrate the effectiveness of their method in both artificially-synthesized and real-world molecules, and highlight its potential applications in quantifying the purity and integrity of vaccine mRNAs and identifying modification hotspots in therapeutic RNA interference molecules. It is important to note that this research has not yet undergone peer review. [Extracted from the article]

A recent study conducted by researchers from the Chinese Academy of Fishery Sciences explores the function of the G2/M phase-specific E3 ubiquitin protein ligase (Cs-g2e3) in gametogenesis in Chinese Tongue Sole. The study found that Cs-g2e3 is predominantly expressed in gonad tissues and its expression peaks at 8 months of age before declining and stabilizing. Knockdown experiments showed that Cs-g2e3 downregulates the expression of key genes involved in oogenesis and spermatogenesis. The study also analyzed mutations in the transcription factor binding sites of Cs-g2e3 and found that they significantly impact its transcriptional activity. This research contributes to a deeper understanding of Cs-g2e3 and its potential regulatory influences. [Extracted from the article]

A researcher from Al-Mustaqbal University College has published a report on tissue engineering and personalized medicine for cholecystitis care. The report discusses advancements in molecular diagnostics and biotherapeutics for diagnosing and treating acute cholecystitis, including next-generation sequencing, phage therapy, RNA interference, CRISPR-Cas9 gene editing, probiotics, robotics, fluorescence imaging, biosensors, regenerative gallbladder tissue engineering, and artificial intelligence. The research concludes that these technologies have the potential to transform the management of cholecystitis, but further research and controlled trials are needed to determine their optimal integration with conventional care. The full report can be accessed for free through the Bulletin of the National Research Centre. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the efficacy of RNA interference (RNAi)-based medicines in rapidly dividing cells, which are important for immune-oncology. The study found that while RNAi therapies have a long duration of effect in non-dividing cells, their effectiveness in rapidly dividing cells is not well understood. The researchers investigated the factors affecting the duration of effect for three types of RNAi-based therapeutics in rapidly dividing cancer and immune cells. They found that modifying the antisense strand of siRNAs with a 5'-(E)-vinylphosphonate significantly extended the silencing duration, while extensive stabilization of the antisense strand with phosphorothioates was not effective for miRNA mimics. The findings provide insights for the design of RNAi-based therapies in oncology and immunology. [Extracted from the article]

A patent has been issued to the University of Massachusetts for a method of therapeutic alteration of transplantable tissues using RNA interference molecules. The invention aims to minimize organ rejection, transmission of viral infections during transplantation, and apoptosis in transplanted tissues. The RNA interference molecules can be delivered to transplantable tissues through various methods, such as perfusion or injection. The patent also includes methods for treating organs at risk of apoptosis-induced ischemic injury. The invention has potential applications in treating various organs, including the kidney, liver, pancreas, heart, and lung. [Extracted from the article]

A recent study conducted by researchers at Hebrew University of Jerusalem has reported positive results for the treatment of primary hyperoxaluria type 1 (PH1) using lumasiran. PH1 is a genetic disorder that can lead to kidney stones, nephrocalcinosis, and kidney failure. Lumasiran, an RNA interference therapeutic, was found to effectively reduce hepatic oxalate production in infants and young children with PH1. The study showed sustained reductions in urinary and plasma oxalate levels over a 30-month period, with stable kidney function and low kidney stone event rates. Mild, transient injection site reactions were the most common side effect of lumasiran. [Extracted from the article]

A recent report from the University of Western Australia discusses the use of polymers to enhance the delivery of antisense oligonucleotides (ASOs) for therapeutic purposes. ASOs are a well-established therapeutic modality based on RNA interference, but they face challenges such as low cellular uptake and limited ability to direct ASO trafficking. The researchers used Nanoscale Secondary Ion Mass Spectrometry (NanoSIMS) to visualize the internalization and dissociation of ASO-polymer complexes at the subcellular level. This information can help improve the understanding of intracellular trafficking pathways and potentially enhance the effectiveness of nucleic acid therapeutics in the future. The research was funded by various organizations, including the Western Australian Future Health and Innovation Fund and the Australian Research Council. [Extracted from the article]

A recent study conducted by researchers at Babes-Bolyai University in Cluj Napoca, Romania, explores the role of epigenetic modifications in gastric cancer (GC). The study highlights the importance of understanding the molecular mechanisms of GC and the role of epigenetic factors in cancer progression. The researchers specifically focus on long noncoding RNAs (lncRNAs) and modifications in N6-methyladenosine (m6A) as significant contributors to epigenetic dysregulation in GC. The integration of genetic and epigenetic considerations is crucial for advancing GC research and developing tailored interventions to improve patient outcomes. Further research is needed to fully understand the complexities of epigenetic modifications in GC. [Extracted from the article]

Researchers at Northwest A&F University in Shaanxi, China have conducted a study on the use of RNA interference (RNAi) as a control strategy against the tomato leafminer, Tuta absoluta. The study focused on targeting two essential genes, voltage-gated sodium channel (Nav) and NADPH-cytochrome P450 reductase (CPR), using an ex vivo tomato leaf delivery system. The researchers found that silencing these genes through RNAi resulted in a reduction in adult emergence and increased susceptibility to the pesticide L-cyholthin in T. absoluta. This study suggests that RNAi targeting key genes could be a potential alternative technology for controlling this destructive tomato pest in the future. [Extracted from the article]

A recent study conducted at Northwestern University in Evanston, Illinois, has identified CASZ1 as an essential activator of epidermal differentiation in the skin. The researchers found that CASZ1 expression is upregulated during epidermal terminal differentiation and impaired in skin disorders such as atopic dermatitis, psoriasis, and squamous cell carcinoma. Through transcriptome profiling and RNA interference, the study identified 674 differentially expressed genes with CASZ1 knockdown, with downregulated genes being enriched for barrier function. The findings suggest that CASZ1 plays a crucial role in maintaining the barrier function of the skin and may have implications for understanding and treating skin diseases. [Extracted from the article]

The patent application titled "Methods Of Placing Locked Nucleic Acids In Small Interfering Rna Strands" outlines a method for introducing locked nucleic acid (LNA) modifications into a nucleic acid strand. This technique aims to develop targeted RNA interference therapy for specific disease-related cells. The method involves determining the secondary structure of the nucleic acid strand, identifying sequence regions, and introducing LNA modifications at specific nucleotides within these regions. The application also includes methods for producing nucleic acid complexes using LNA-modified nucleic acid strands. The patent application provides detailed information and methods for implementing this technique. [Extracted from the article]

Dicerna Pharmaceuticals Inc. has been issued a patent for extended dicer substrate agents and methods for the specific inhibition of gene expression. The patent describes the use of double-stranded nucleic acid agents to reduce the expression of target genes in mammalian cells. These agents have specific structural characteristics, including a single-stranded nucleotide region, that enhance their efficacy and other attributes. The patent also covers pharmaceutical compositions containing these agents and methods for administering them to humans to reduce target gene expression. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the use of RNA-guided RNA cutting systems, specifically Cas13d, for biotechnological and therapeutic purposes. The study focuses on the collateral damage caused by off-target cutting and the dependence of RNA target reduction on Cas13d and guide RNA levels. The researchers develop new gene circuits called MONARCH that achieve a high dynamic range with low basal on-target RNA reduction and minimal collateral activity in human kidney cells and green monkey cells. The study suggests that MONARCH could be a valuable tool for transcriptome engineering in biotechnological and medical applications. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

This article discusses the role of genomic duplications in contributing to insecticide resistance in the dengue mosquito Aedes aegypti. The study found that a large genomic duplication affecting a cluster of detoxification enzymes was associated with resistance to the insecticide deltamethrin. The duplication enhanced the expression of multiple cytochrome P450s in the resistant mosquitoes. The research provides new insights into the evolutionary processes underlying rapid adaptation and offers potential tools for surveillance and management of resistance in the field. [Extracted from the article]

A recent study conducted by researchers at the State University of New York (SUNY) Albany has shed light on the mechanisms of the Zika virus (ZIKV) and its impact on cellular stress pathways and transcriptional programs. The study found that the activation of the stress-induced transcriptional effector, Activating Transcription Factor 3 (ATF3), plays a crucial role in limiting ZIKV gene expression and enhancing the innate immune response to combat the virus. This research expands our understanding of the transcriptional mechanisms and control of host defense pathways during ZIKV infection. [Extracted from the article]

A patent application titled "Methods And Systems For Identifying Target Genes" has been published online. The application discusses the need for improved methods of identifying genomic regions for therapeutic targeting in order to re-program cells from one phenotypic state to another. The application outlines high-content, high-efficiency, and high-throughput CRISPR screening techniques to identify target genes that may mediate re-programming between different cellular states. It also explores the use of anomaly detection models to quantify re-programming and select biomarkers and therapeutic targets for specific diseases. The invention has potential applications in identifying therapeutic targets and treating diseases. [Extracted from the article]

A patent application titled "Compositions And Methods Of Treating Facioscapulohumeral Muscular Dystrophy" has been published online. The inventors have developed polynucleic acid molecules and pharmaceutical compositions for treating muscle atrophy, specifically Facioscapulohumeral muscular dystrophy (FSHD). The patent application describes the use of polynucleic acid molecules that can hybridize to a target sequence and mediate RNA interference against it, as well as polynucleic acid molecule conjugates that can be used to modulate symptoms of muscle dystrophy. The patent application provides detailed claims and sequences of the polynucleic acid molecule. [Extracted from the article]

The article presents the discussion on relationship between BRCA1 gene methylation and breast cancer cell radiosensitivity, revealing that RNA interference can enhance radiosensitivity by increasing BRCA1 methylation. Topics include the impact of RNA interference on BRCA1 gene expression, the use of lentivirus-mediated shRNA for targeted gene modification; and the effects on DNA repair and cell survival after irradiation.

A recent report discusses research on the hepatitis E virus (HEV) and its global health impact. The study, conducted by researchers at Technical University Berlin (TU Berlin), explores the use of RNA interference (RNAi) and RIG-I activation as potential strategies to inhibit HEV replication. The researchers designed small interfering RNAs (siRNAs) that effectively inhibited viral replication in infected cells. Additionally, they found that a modification on the siRNA sense strand activated the RIG-I receptor, which further suppressed HEV replication. This dual-action strategy shows promise for the development of new therapies against HEV. [Extracted from the article]

A new report from Army Medical University researchers in Chongqing, China, presents fresh data on malaria. The researchers investigated the effect of human defensin 5 (HD5) on the development of Plasmodium yoelii, the parasite that causes malaria, in Anopheles stephensi mosquitoes. They found that HD5 treatment reduced the infection density of Plasmodium yoelii in the mosquitoes and upregulated the expression of innate immune effectors. The researchers concluded that HD5 inhibits the development of malaria parasites in mosquitoes by activating the Toll signaling pathway. This research provides insights into potential novel strategies for controlling malaria. [Extracted from the article]

Researchers from Shenyang Agricultural University in China have conducted a study on LDL receptors and their role in the toxicity of Binary toxins from Lysinibacillus sphaericus to Ag55 cells. The study focused on the scavenger receptor C1 (SCRC1) as a potential mediator of Bin toxin cytotoxicity. Through RNA interference knockdown experiments, the researchers found that SCRC1 plays a crucial role in the endocytosis of Bin toxin into Ag55 cells, facilitating its cytological activity. This research provides new insights into the mechanism of Bin toxin action and encourages further investigation into the transfer of Bin toxin within the cells. [Extracted from the article]

A new report from Nanjing University of Chinese Medicine highlights the potential neurotoxicity of nanoplastics. The study compared the transgenerational effects of pristine polystyrene nanoplastics (PS-NP) and amino-modified PS-NP (NH2-PS-NP) on the nematode Caenorhabditis elegans. The results showed that NH2-PS-NP caused more severe transgenerational toxicity on locomotion and neuronal development compared to PS-NP. The study suggests that amino-modified nanoplastics may pose a greater risk of neurotoxicity at environmentally relevant doses. [Extracted from the article]

A recent study conducted by Yonsei University College of Medicine has found that dysregulation of iron metabolism is linked to the development and progression of colorectal cancer (CRC). The study focused on the role of iron regulatory protein 2 (IRP2) in promoting tumor growth in CRC. The researchers discovered that inhibiting IRP2 resulted in a significant delay in tumor growth and developed IRP2 inhibitors that reduced IRP2 expression and hindered its interaction with iron-responsive elements. These findings suggest that targeting IRP2 could be a potential therapeutic strategy for CRC treatment. [Extracted from the article]

Researchers from the National University of Cordoba in Argentina have discovered that the clock gene period (per) plays a role in regulating the expression of genes related to insecticide resistance in the Chagas disease vector, Triatoma infestans. The study found that silencing the per gene disrupted circadian rhythms and reduced the expression of genes associated with insecticide resistance. This research provides insight into the biological clock's involvement in regulating gene expression in the Chagas disease vector. The study has been peer-reviewed and published in Acta Tropica. [Extracted from the article]